109 related articles for article (PubMed ID: 32453574)
1. Cyclo-RGD Truncated Polymeric Nanoconstruct with Dendrimeric Templates for Targeted HDAC4 Gene Silencing in a Diabetic Nephropathy Mouse Model.
Raval N; Jogi H; Gondaliya P; Kalia K; Tekade RK
Mol Pharm; 2021 Feb; 18(2):641-666. PubMed ID: 32453574
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy.
Wang X; Liu J; Zhen J; Zhang C; Wan Q; Liu G; Wei X; Zhang Y; Wang Z; Han H; Xu H; Bao C; Song Z; Zhang X; Li N; Yi F
Kidney Int; 2014 Oct; 86(4):712-25. PubMed ID: 24717296
[TBL] [Abstract][Full Text] [Related]
3. Method and its Composition for encapsulation, stabilization, and delivery of siRNA in Anionic polymeric nanoplex: An In vitro- In vivo Assessment.
Raval N; Jogi H; Gondaliya P; Kalia K; Tekade RK
Sci Rep; 2019 Nov; 9(1):16047. PubMed ID: 31690769
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 4 mediates high glucose-induced podocyte apoptosis via upregulation of calcineurin.
Shi W; Huang Y; Zhao X; Xie Z; Dong W; Li R; Chen Y; Li Z; Wang W; Ye Z; Liu S; Zhang L; Liang X
Biochem Biophys Res Commun; 2020 Dec; 533(4):1061-1068. PubMed ID: 33019979
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
[TBL] [Abstract][Full Text] [Related]
6. Silencing of Histone Deacetylase 9 Expression in Podocytes Attenuates Kidney Injury in Diabetic Nephropathy.
Liu F; Zong M; Wen X; Li X; Wang J; Wang Y; Jiang W; Li X; Guo Z; Qi H
Sci Rep; 2016 Sep; 6():33676. PubMed ID: 27633396
[TBL] [Abstract][Full Text] [Related]
7. HDAC4 blocks autophagy to trigger podocyte injury: non-epigenetic action in diabetic nephropathy.
Wei Q; Dong Z
Kidney Int; 2014 Oct; 86(4):666-8. PubMed ID: 25265947
[TBL] [Abstract][Full Text] [Related]
8. Engineered nanoplex mediated targeted miRNA delivery to rescue dying podocytes in diabetic nephropathy.
Raval N; Gondaliya P; Tambe V; Kalia K; Tekade RK
Int J Pharm; 2021 Aug; 605():120842. PubMed ID: 34216766
[TBL] [Abstract][Full Text] [Related]
9. Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat.
Khan S; Jena G; Tikoo K
Exp Mol Pathol; 2015 Apr; 98(2):230-9. PubMed ID: 25576297
[TBL] [Abstract][Full Text] [Related]
10. Zinc oxide nanoparticles prevent the onset of diabetic nephropathy by inhibiting multiple pathways associated with oxidative stress.
Padhye-Pendse A; Umrani R; Paknikar K; Jadhav S; Rajwade J
Life Sci; 2024 Jun; 347():122667. PubMed ID: 38670449
[TBL] [Abstract][Full Text] [Related]
11. Valproate attenuates the proteinuria, podocyte and renal injury by facilitating autophagy and inactivation of NF-κB/iNOS signaling in diabetic rat.
Khan S; Jena G; Tikoo K; Kumar V
Biochimie; 2015 Mar; 110():1-16. PubMed ID: 25572918
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase.
Lee JH; Sarker MK; Choi H; Shin D; Kim D; Jun HS
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1332-1340. PubMed ID: 30763641
[TBL] [Abstract][Full Text] [Related]
13. Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC.
Dong W; Jia Y; Liu X; Zhang H; Li T; Huang W; Chen X; Wang F; Sun W; Wu H
J Endocrinol; 2017 Jan; 232(1):71-83. PubMed ID: 27799462
[TBL] [Abstract][Full Text] [Related]
14. Geniposide alleviates diabetic nephropathy of mice through AMPK/SIRT1/NF-κB pathway.
Li F; Chen Y; Li Y; Huang M; Zhao W
Eur J Pharmacol; 2020 Nov; 886():173449. PubMed ID: 32758570
[TBL] [Abstract][Full Text] [Related]
15. Dopamine 1 receptor activation protects mouse diabetic podocytes injury via regulating the PKA/NOX-5/p38 MAPK axis.
Shao X; Zhang X; Hu J; Gao T; Chen J; Xu C; Wei C
Exp Cell Res; 2020 Mar; 388(2):111849. PubMed ID: 31954110
[TBL] [Abstract][Full Text] [Related]
16. Silencing PEG3 inhibits renal fibrosis in a rat model of diabetic nephropathy by suppressing the NF-κB pathway.
Guan T; Fang F; Su X; Lin K; Gao Q
Mol Cell Endocrinol; 2020 Aug; 513():110823. PubMed ID: 32311421
[TBL] [Abstract][Full Text] [Related]
17. Study on the inhibitive effect of Catalpol on diabetic nephropathy.
Chen J; Yang Y; Lv Z; Shu A; Du Q; Wang W; Chen Y; Xu H
Life Sci; 2020 Sep; 257():118120. PubMed ID: 32693244
[TBL] [Abstract][Full Text] [Related]
18. Yishen capsule promotes podocyte autophagy through regulating SIRT1/NF-κB signaling pathway to improve diabetic nephropathy.
Liu Y; Liu W; Zhang Z; Hu Y; Zhang X; Sun Y; Lei Q; Sun D; Liu T; Fan Y; Li H; Ding W; Fang J
Ren Fail; 2021 Dec; 43(1):128-140. PubMed ID: 33427556
[TBL] [Abstract][Full Text] [Related]
19. Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway.
Zhu L; Han J; Yuan R; Xue L; Pang W
Biol Res; 2018 Mar; 51(1):9. PubMed ID: 29604956
[TBL] [Abstract][Full Text] [Related]
20. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways.
Malik S; Suchal K; Khan SI; Bhatia J; Kishore K; Dinda AK; Arya DS
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F414-F422. PubMed ID: 28566504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
